

해외 바이오의약품 임상 현황 (2020.04.20~2020.04.26)

한국바이오의약품협회, 2020.4.28.
출처: ClinicalTrials.gov

○ 미국 13건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04364178	Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV	Adenovirus Cytomegalovirus Infections Epstein-Barr Virus Infections	Biological: Adenovirus Specific T-Lymphocytes Biological: Cytomegalovirus Specific T-Lymphocytes Biological: Epstein-Barr Virus Specific T-Lymphocytes	Jessie Barnum University of Pittsburgh	Phase 1 Phase 2
NCT04349267	Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	Biological: BMS-986315 Biological: nivolumab Biological: cetuximab	Bristol-Myers Squibb	Phase 1 Phase 2
NCT04362176	Passive Immunity Trial of Nashville II	COVID-19 Coronavirus SARS-CoV-2	Biological: pathogen reduced SARS-CoV-2 convalescent plasma Biological: Placebo	Vanderbilt University Medical Center Dolly Parton	Phase 3
NCT04348435	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19	COVID-19	Drug: HB-adMSCs Drug: Placebos	Hope Biosciences Hope Biosciences Stem Cell Research Foundation	Phase 2
NCT04342897	A Study of LY3127804 in Participants With COVID-19	COVID-19 Pneumonia	Drug: LY3127804 Drug: Placebo	Eli Lilly and Company	Phase 2
NCT04340882	Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade	Metastatic Non-Small Lung Cell Cancer Recurrent Non-Small Lung Cell Cancer Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Drug: Docetaxel Biological: Pembrolizumab Biological: Ramucirumab	Emory University National Cancer Institute (NCI) Merck Sharp & Dohme Corp.	Phase 2
NCT04331899	Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19	COVID-19	Drug: Peginterferon Lambda-1a Other: Placebo	Stanford University	Phase 2
NCT04318379	Therapeutic Hepatitis C Virus Vaccine	Chronic Hepatitis C Infection	Biological: HCVax	GeneCure Biotechnologies	Phase 1
NCT04344795	Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors	Solid Tumor Microsatellite-stable Colorectal Cancer (MSS CRC) Adenocarcinoma of the Lung Squamous Cell Carcinoma of Head and Neck Bladder Cancer Triple Negative Breast Cancer Gastric Cancer	Drug: TPST-1495 Drug: Pembrolizumab	Tempest Therapeutics	Phase 1
NCT04205812	Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)	Metastatic Squamous Non-Small Cell Lung Cancer Metastatic Nonsquamous Non-Small Cell Lung Cancer	Drug: Retifanlimab Drug: Placebo Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: Paclitaxel Drug: nab-Paclitaxel	Incyte Corporation Zai Lab (Shanghai) Co., Ltd.	Phase 3
NCT04301011	Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors	Solid Tumor Triple Negative Breast Cancer Microsatellite Stable Colorectal Cancer	Biological: TBio-6517 Biological: Pembrolizumab	Turnstone Biologics, Corp. Takeda	Phase 1 Phase 2
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

해외 바이오의약품 임상 현황 (2020.04.20~2020.04.26)

한국바이오의약품협회, 2020.4.28.
출처: ClinicalTrials.gov

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04348643	Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer	Solid Tumor Lung Cancer Colorectal Cancer Liver Cancer Pancreatic Cancer Gastric Cancer Breast Cancer	Biological: CEA CAR-T cells	Chongqing Precision Biotech Co., Ltd	Phase 1 Phase 2
NCT04212221	MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients	Advanced Hepatocellular Carcinoma (HCC)	Drug: MGD013 monotherapy Drug: MGD013 in combination with Brivanib Alaninate	Zai Lab (Shanghai) Co., Ltd.	Phase 1 Phase 2
NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma	Drug: Toripalimab Drug: R-CHOP Protocol	Huiqiang Huang Sun Yat-sen University	Phase 1 Phase 2
NCT04325698	A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC	Advanced Non-squamous NSCLC	Drug: PF-06439535 (CN) Drug: Bevacizumab-EU Drug: Paclitaxel Drug: Carboplatin	Pfizer	Phase 3

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3